Cervical Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Cervical cancer is one of the most common malignancies in the female genital tract system. It is the second leading cause of cancer mortality in women aged 20 to 39 years. The prognosis of cervical cancer patients remains poor, especially in metastatic patients. Previous studies have shown that the median survival time of metastatic cervical cancer is only 8-13 months, and the 5-year survival rate is 16.5%. Due to the poor prognosis, metastatic cervical cancer has become one of the main challenges in the world. In metastatic and recurrent Cervical cancer, Single-site metastasis accounted for 68.7%, and multi-organ metastases were relatively rare. In single-site metastasis, lung metastasis was the most common, accounting for 37.9% of all patients, followed by bone metastasis (16.7%) and liver metastasis (12.5%).

·       Brain metastases were uncommon, only accounted for 1.6%. In patients with multi-organ metastases, lung plus liver metastases and lung plus bone metastases were more common than other multi-organ metastases.

Thelansis’s “Cervical Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cervical Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Cervical Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Cervical Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Cervical Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033